GRTS News and Press, Gritstone Oncology Inc. From 01/04/21

EcoR1 Capital disclosed a 9.99% stake in Gritstone Oncology (GRTS), which represents over 4.87M shares.The filing does not allow for activism.Shares +9.3% during after hours. For further details see: Gritstone Oncology +9.3% AH, EcoR1 discloses ~10% stake in company

Gainers: Bionano Genomics (BNGO) +82%, DermTech (DMTK) +25%, IMAC Holdings (IMAC) +20%, Gritstone Oncology (GRTS) +15%, Hepion Pharmaceuticals (HEPA) +12%.Losers: Regional Health Properties (RHE) -20%, Osmotica Pharmaceuticals (OSMT) -20%, Equ...

Gritstone Oncology ([[GRTS]] +1.4%) announces $110M private investment in public equity financing.Also, a newly executed PIPE financing for an additional $15M in gross proceeds resulting from the sale of shares at a price per share of $3.71. Gross proceeds from the two PIPE financings to...

--Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing-- --Executed Additional PIPE Financing of $15 Million-- EMERYVILLE, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company deve...

Gritstone Oncology (GRTS) has executed a securities purchase agreement to raise $110M in gross proceeds via sale of common stock and/or pre-funded warrants through a private investment in public equity financing at $3.34/share.Net proceeds will be used to fund research and development expense...

EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has executed a securities purchase agreement...

Gritstone Oncology (GRTS) has announced that Jean-Marc Bellemin has resigned as Chief Financial Officer effective December 11  to pursue other opportunities, and the company has commenced an executive search for a new CFO. For further details see: Gritstone Onco...

EMERYVILLE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the third quarter ended Septemb...

Gritstone Oncology (GRTS) has begun dosing patients in the Phase 2 expansion cohorts of the Phase 1/2 clinical studies for GRANITE and SLATE, its neoantigen-based immunotherapies. The company expects to present the full dataset by mid-2021. The Phase 2 portion of the GRANITE Phase 1/2 study (...

-- The Phase 1 portion s of the stud ies are closed for enrollment ; patient trea tment and follow -up for efficacy and safety continues -- EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. ...